FIELD: biotechnology; medicine.
SUBSTANCE: disclosed are genetic labels operably linked to transgenes. Expression of the genetic label provides identification, detection, selection, and ablation of cells expressing the transgene and the genetic label.
EFFECT: invention provides compositions and methods for selecting and/or detecting cells which express high levels of transgenes.
34 cl, 9 dwg, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TRANSGENIC GENETIC LABELS AND METHODS OF USING | 2015 |
|
RU2729112C2 |
| DRUG-REGULATED TRANSGENIC EXPRESSION | 2015 |
|
RU2751920C2 |
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2015 |
|
RU2752275C2 |
| MODIFIED HEMATOPOIETIC STEM CELLS/PROGENITOR CELLS AND NON-T EFFECTOR CELLS, AND USE THEREOF | 2014 |
|
RU2733652C2 |
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
